No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 23.1x · 10Y median 70.2x · 6th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 11
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T12:01:18.311Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for BioAge Labs Inc. (BIOA) stock was $6.36 as of Oct 5, 2026, 4:00 PM EDT, down 3.78% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +13.3%
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Biotechnology · Emeryville, CA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.66
Revenue Est.
$1.53M
Last Quarter Results
EPS
$-0.58
vs Estimate
$-0.62
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BIOA | $239.45M | $6.36 | -3.78% | +13.30% | N/A | N/A | N/A |
| 2BDSX | $236.56M | $29.06 | +4.83% | +273.09% | -28.49% | N/A | vs BIOA |
| 3AKBA | $244.25M | $0.91 | +5.26% | -67.65% | -20.07% | -20.53% | vs BIOA |
| 4GALT | $245.65M | $3.73 | -4.36% | -13.80% | +0.60% | +13.41% | vs BIOA |
| 5GLSI | $248.21M | $16.91 | -0.41% | +54.67% | -14.84% | N/A | vs BIOA |
| 6CAMP | $251.64M | $4.01 | +0.25% | +32.17% | N/A | N/A | vs BIOA |
forward FY estimate
N/A
$2.45M
vs Estimate
$1.50M
Consensus Rating
Based on 8 analysts
Average Price Target
$35.63
+460.1% upside
Low
$20.00
Current
$6.36
High
$73.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.82 | $-0.62 | $-0.40 | 6 |
| Quarter ending Dec 2026 | $-0.89 | $-0.66 | $-0.41 | 6 |
| Quarter ending Mar 2027 | $-0.87 | $-0.55 | $-0.23 | 2 |
| Quarter ending Jun 2027 | $-0.94 | $-0.59 | $-0.25 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.89 | $-2.43 | $-1.92 | 6 |
| FY 2027 | $-2.64 | $-2.17 | $-1.79 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $850308.00 | $1.53M | $2.21M | 5 |
| Quarter ending Dec 2026 | $704259.00 | $1.27M | $1.83M | 5 |
| Quarter ending Mar 2027 | $97222.00 | $175000.00 | $252777.00 | 4 |
| Quarter ending Jun 2027 | $97222.00 | $175000.00 | $252777.00 | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $6.49M | $7.62M | $10.00M | 8 |
| FY 2027 | $1.03M | $15.67M | $25.76M | 7 |
